This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Otherwise, this looks like a fantastic growth stock that just doubled its addressable market with the Zava acquisition. Today ...

A high-level overview of Novo Nordisk A/S (NONOF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...